8至11岁肥胖儿童GLP-1受体激动剂处方趋势:2019-2026
结果显示,处方率从2019年的0.03%上升至2026年的9.3%,增长310倍(P < .001),但总体仅0.6%的儿童接受了处方。年龄较大、女性、社会脆弱性较低以及合并肥胖相关疾病的儿童更可能被处方。
要点
- 2019至2026年,8-11岁肥胖儿童GLP-1RA处方率从0.03%升至9.3%,增长310倍。
- 总体处方率仍低(0.6%),临床医生可能将GLP-1RA保留给心血管代谢风险最高的儿童。
核心结论
- 临床医生似乎将GLP-1RA保留给心血管代谢风险最高的儿童,且处方更可能给予社会脆弱性较低的儿童。
研究设计与样本
- 回顾性横断面研究,采用Epic Cosmos重复年度队列,纳入2019年1月1日至2026年6月17日期间8-11岁无糖尿病且肥胖的儿童。
- 使用分组数据的二项逻辑回归模型检验处方比例随时间的变化是否具有统计学显著性。
主要发现
- 处方率从2019年的0.03%上升至2026年的9.3%,增长310倍(P < .001)。
关键数值与推荐
- 临床实践指南允许在8-11岁儿童中考虑使用GLP-1受体激动剂。
- 研究分析了Saxenda、Wegovy和Zepbound的处方。
临床怎么用
- 对于8-11岁肥胖且无糖尿病的儿童,GLP-1RA处方在2019-2026年间大幅增加,但总体仍不常见,提示临床选择可能集中于高风险患者。
- 处方分布显示社会脆弱性较低的儿童更可能获得GLP-1RA,需关注处方公平性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Clinical practice guidelines for pediatric obesity management allow for consideration of glucagon-like peptide-1 receptor agonists (GLP-1RA) in children ages 8-11. No study has documented secular trends in GLP-1RA prescribing in this group. We hypothesized that there would be a significant increase over time, particularly for children with more severe obesity, greater comorbidity burden, and less socioeconomic vulnerability. METHODS: This retrospective cross-sectional study of repeated annual cohorts from Epic Cosmos examined GLP-1RA prescriptions (Saxenda, Wegovy, Zepbound) for children (aged 8-11) without diabetes and with obesity from January 1, 2019 to June 17, 2026. A binomial logistic regression model for grouped data was performed to determine whether changes in the proportion of patients prescribed GLP-1RA over time were statistically significant. RESULTS: Among 3 520 531 children with obesity but without diabetes, 0.6% received a GLP-1RA prescription. Older children (11 years: 79.5/10 000 vs 8 years: 41.5/10 000), female children (75.9/10 000 vs 42.8/10 000), and children with less social vulnerability (low: 76.1/10 000 vs high: 49.2/10 000) were more likely to be prescribed GLP-1RAs. Children with obesity-related comorbidities were substantially more likely to be prescribed GLP-1RAs (188.9/10 000). Prevalent prescribing increased from 0.03% in 2019 to 9.3% in 2026, a 310-fold increase (P < .001). CONCLUSIONS: In this cohort of >3.5 million children aged 8 to 11 with obesity and without diabetes, GLP-1RA prescribing increased sharply from 2019 to 2026 yet remained uncommon, reaching 0.6% of children. Clinicians appear to be reserving GLP-1RAs for those at greatest cardiometabolic risk. Prescriptions are more likely to go to those with less socioeconomic vulnerability.
引用
- Orandi BJ, Patel SS, Messito MJ, et al. Trends in GLP-1 Receptor Agonist Prescriptions for Children Ages 8 to 11 With Obesity: 2019-2026. Pediatrics. 2026. PMID: 42692477. doi:10.1542/peds.2026-077048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。